Will we be able to predict in which atrial fibrillation patients a rhythm control strategy will be successful?

Europace

Volumn 11, Issue 7, 2009, Pages 846-847

  Smit, Marcelle D ^a   Van Gelder, Isabelle C ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; C REACTIVE PROTEIN;

APNEA; CARDIOVERSION; DISEASE SEVERITY; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART VENTRICLE REMODELING; HUMAN; PATIENT SELECTION; POLYSOMNOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SINUS RHYTHM; SLEEP APNEA SYNDROME; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 67650901948     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup148     Document Type: Editorial

References (10)

1. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030.
3. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:1784-92.
4. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. Europace 2008;10:668-73.
5. Mazza M, Bendini MG, Cristofori M, Nardi S, Leggio M, De Cristofaro R et al. Baseline apnoea/hypopnoea index and high-sensitivity C-reactive protein for the risk of recurrence of atrial fibrillation after successful electrical cardioversion: a predictive model based upon the multiple effects of significant variables. Europace 2009;11:902-9.
6. Jongnarangsin K, Chugh A, Good E, Mukerji S, Dey S, Crawford T et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:668-72.
7. Stevenson IH, Teichtahl H, Cunnington D, Ciavarella S, Gordon I, Kalman JM. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J 2008;29:1662-9.
8. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.
9. Smit MD, Van Gelder IC. Is inflammation a risk factor for recurrent atrial fibrillation? Europace 2009;11:138-9.
10. Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirchhof P et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008;10:21-7.